Key Insights

Highlights

Success Rate

82% trial completion

Published Results

16 trials with published results (14%)

Research Maturity

60 completed trials (51% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

11.0%

13 terminated out of 118 trials

Success Rate

82.2%

-4.3% vs benchmark

Late-Stage Pipeline

7%

8 trials in Phase 3/4

Results Transparency

27%

16 of 60 completed with results

Key Signals

16 with results82% success13 terminated

Data Visualizations

Phase Distribution

86Total
Not Applicable (14)
P 1 (18)
P 2 (46)
P 3 (7)
P 4 (1)

Trial Status

Completed60
Unknown21
Terminated13
Recruiting12
Active Not Recruiting6
Not Yet Recruiting3

Trial Success Rate

82.2%

Benchmark: 86.5%

Based on 60 completed trials

Clinical Trials (118)

Showing 20 of 20 trials
NCT02012699Recruiting

Integrated Cancer Repository for Cancer Research

NCT04907643Not ApplicableRecruiting

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

NCT07146646Phase 2Recruiting

Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer

NCT06192719RecruitingPrimary

EULAT Eradicate GBC

NCT05489250Terminated

The PLATON Network

NCT02293954Not ApplicableActive Not Recruiting

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

NCT06123117Not ApplicableRecruiting

STALL vs Sole Local Wound Infiltration in Laparoscopic Cholecystectomy

NCT04871321Completed

Biomarker Discovery in Patients With Advanced Biliary Tract Cancer

NCT07092397CompletedPrimary

Artificial Intelligence-based Tumor Microenvironment Analysis for Prognosis Prediction in Gallbladder Cancer

NCT04561453Terminated

Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer

NCT05253053Phase 1Completed

To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

NCT05712356Phase 2Active Not Recruiting

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

NCT06531408Active Not RecruitingPrimary

Predicting Incidental Gallbladder Cancer

NCT06963060Phase 2Enrolling By InvitationPrimary

Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)

NCT04383210Phase 2Terminated

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

NCT04484636Not ApplicableCompleted

PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)

NCT06223061Completed

Global Evaluation of Cholecystectomy Knowledge and Outcomes

NCT04308174Phase 2Active Not Recruiting

Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer

NCT06787807Not ApplicableNot Yet Recruiting

Proteomic Analysis of Patients Undergoing Bariatric Surgery

NCT01640522Not ApplicableCompleted

Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms

Scroll to load more

Research Network

Activity Timeline